Results 1 to 10 of about 308,124 (370)

A modular protein language modelling approach to immunogenicity prediction. [PDF]

PLoS Computational Biology
Neoantigen immunogenicity prediction is a highly challenging problem in the development of personalised medicines. Low reactivity rates in called neoantigens result in a difficult prediction scenario with limited training datasets.
Hugh O'Brien, Max Salm, Laura T Morton, Maciej Szukszto, Felix O'Farrell, Charlotte Boulton, Laurence King, Supreet Kaur Bola, Pablo D Becker, Andrew Craig, Morten Nielsen, Yardena Samuels, Charles Swanton, Marc R Mansour, Sine Reker Hadrup, Sergio A Quezada   +15 more
doaj   +2 more sources

Immunogenicity Risk Profile of Nanobodies

Frontiers in Immunology, 2021
Nanobodies (Nbs), the variable domains of camelid heavy chain-only antibodies, are a promising class of therapeutics or in vivo imaging reagents entering the clinic.
Chloé Ackaert, Natalia Smiejkowska, Catarina Xavier, Yann G. J. Sterckx, Yann G. J. Sterckx, Sofie Denies, Benoit Stijlemans, Benoit Stijlemans, Yvon Elkrim, Nick Devoogdt, Vicky Caveliers, Vicky Caveliers, Tony Lahoutte, Tony Lahoutte, Serge Muyldermans, Karine Breckpot, Marleen Keyaerts, Marleen Keyaerts   +17 more
doaj   +2 more sources

Sleep and vaccine administration time as factors influencing vaccine immunogenicity [PDF]

Kosin Medical Journal, 2022
The immunogenicity of vaccines is affected by host, external, environmental, and vaccine factors; in addition, sleep or circadian rhythms may also have effects.
Eun Seok Kim, Chi Eun Oh
doaj   +1 more source

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

New England Journal of Medicine, 2021
Background Until very recently, vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had not been authorized for emergency use in persons younger than 16 years of age.
R. Frenck, N. Klein, N. Kitchin, A. Gurtman, J. Absalon, S. Lockhart, John L. Perez, E. Walter, S. Senders, R. Bailey, K. Swanson, Hua Ma, Xia Xu, K. Koury, W. Kalina, David Cooper, T. Jennings, Donald M Brandon, Stephen J. Thomas, Ö. Türeci, D. Tresnan, Susan H. Mather, P. Dormitzer, U. Şahin, K. Jansen, W. Gruber   +25 more
semanticscholar   +1 more source

A Regulatory Risk-Based Approach to ATMP/CGT Development: Integrating Scientific Challenges With Current Regulatory Expectations

Frontiers in Medicine, 2022
Cell and Gene Therapy Products (CGT), regulated as Advanced Therapy Medicinal Products (ATMP) in the European Union (EU), represent a novel and varied group of biotherapeutics developed to treat specific conditions for which there are limited or no ...
Laura I. Salazar-Fontana, Laura I. Salazar-Fontana, Laura I. Salazar-Fontana   +2 more
doaj   +1 more source

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study

Annals of the Rheumatic Diseases, 2021
Introduction Vaccination represents a cornerstone in mastering the COVID-19 pandemic. Data on immunogenicity and safety of messenger RNA (mRNA) vaccines in patients with autoimmune inflammatory rheumatic diseases (AIIRD) are limited.
V. Furer, T. Eviatar, D. Zisman, H. Peleg, D. Paran, D. Levartovsky, M. Zisapel, O. Elalouf, I. Kaufman, R. Meidan, A. Broyde, A. Polachek, J. Wollman, I. Litinsky, K. Meridor, H. Nochomovitz, Adi Silberman, D. Rosenberg, J. Feld, A. Haddad, Tal Gazzit, M. Elias, N. Higazi, F. Kharouf, G. Shefer, O. Sharon, S. Pel, S. Nevo, O. Elkayam   +28 more
semanticscholar   +1 more source

Human leukocyte antigen class II quantification by targeted mass spectrometry in dendritic-like cell lines and monocyte-derived dendritic cells

Scientific Reports, 2021
The major histocompatibility complex II (HLA-II) facilitates the presentation of antigen-derived peptides to CD4+ T-cells. Antigen presentation is not only affected by peptide processing and intracellular trafficking, but also by mechanisms that govern ...
A. Casasola-LaMacchia, M. S. Ritorto, R. J. Seward, N. Ahyi-Amendah, A. Ciarla, T. P. Hickling, H. Neubert   +6 more
doaj   +1 more source

Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients.

Journal of the American Medical Association (JAMA), 2021
Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients Immunocompromised individuals have been excluded from studies of SARS-CoV-2 messenger RNA (mRNA) vaccines.
B. Boyarsky, William Werbel, R. Avery, A. Tobian, A. Massie, D. Segev, J. Garonzik‐Wang   +6 more
semanticscholar   +1 more source

Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women.

Journal of the American Medical Association (JAMA), 2021
Importance Pregnant women are at increased risk of morbidity and mortality from COVID-19 but have been excluded from the phase 3 COVID-19 vaccine trials. Data on vaccine safety and immunogenicity in these populations are therefore limited. Objective To
Ai-ris Y. Collier, K. McMahan, Jingyou Yu, Lisa H. Tostanoski, R. Aguayo, J. Ansel, A. Chandrashekar, Shivani Patel, E. Apraku Bondzie, D. Sellers, J. Barrett, O. Sanborn, H. Wan, A. Chang, T. Anioke, Joseph P. Nkolola, C. Bradshaw, C. Jacob-Dolan, J. Feldman, M. Gebre, E. Borducchi, Jinyan Liu, A. Schmidt, T. Suscovich, C. Linde, G. Alter, M. Hacker, D. Barouch   +27 more
semanticscholar   +1 more source

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

New England Journal of Medicine, 2020
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and the resulting disease, coronavirus disease 2019 (Covid-19), have spread to millions of persons worldwide.
E. Walsh, R. Frenck, A. Falsey, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, K. Neuzil, M. Mulligan, R. Bailey, K. Swanson, Ping Li, K. Koury, W. Kalina, David Cooper, Camila R. Fontes-Garfias, P. Shi, Ö. Türeci, Kristin Tompkins, K. Lyke, V. Raabe, P. Dormitzer, K. Jansen, U. Şahin, W. Gruber   +24 more
semanticscholar   +1 more source